These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12172322)

  • 1. Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension.
    Dao HH; Essalihi R; Graillon JF; Larivière R; De Champlain J; Moreau P
    J Hypertens; 2002 Aug; 20(8):1597-606. PubMed ID: 12172322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new model of isolated systolic hypertension induced by chronic warfarin and vitamin K1 treatment.
    Essalihi R; Dao HH; Yamaguchi N; Moreau P
    Am J Hypertens; 2003 Feb; 16(2):103-10. PubMed ID: 12559675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aortic smooth muscle cell phenotypic modulation and fibrillar collagen deposition in angiotensin II-dependent hypertension.
    Rossi GP; Cavallin M; Belloni AS; Mazzocchi G; Nussdorfer GG; Pessina AC; Sartore S
    Cardiovasc Res; 2002 Jul; 55(1):178-89. PubMed ID: 12062721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.
    Chrysant SG; Neutel JM; Ferdinand KC;
    J Natl Med Assoc; 2009 Apr; 101(4):300-7. PubMed ID: 19397219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies.
    Omboni S; Malacco E; Napoli C; Modesti PA; Manolis A; Parati G; Agabiti-Rosei E; Borghi C
    Adv Ther; 2017 Apr; 34(4):784-798. PubMed ID: 28260186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
    Schiffrin EL; Park JB; Pu Q
    J Hypertens; 2002 Jan; 20(1):71-8. PubMed ID: 11791028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter Randomized Double-Blind Comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the Treatment of Isolated Systolic Hypertension in Elderly Patients: Results of the NEHIS Study.
    Grassi G; Seravalle G; Brambilla G; Dell'Oro R; Trevano FQ; Fici F; van Bortel L; Mancia G
    Adv Ther; 2017 Jan; 33(12):2173-2187. PubMed ID: 27771847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The control rate of irbesartan/hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension].
    Sun NL; Jing S; Chen J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Jul; 33(7):618-21. PubMed ID: 16080809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
    Lewin AJ; Weir MR
    Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats.
    Brosnan MJ; Hamilton CA; Graham D; Lygate CA; Jardine E; Dominiczak AF
    J Hypertens; 2002 Feb; 20(2):281-6. PubMed ID: 11821713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the composition of the thoracic aortic wall in spontaneously hypertensive rats treated with losartan or spironolactone.
    Han WQ; Wu LY; Zhou HY; Zhang J; Che ZQ; Wu YJ; Liu JJ; Zhu DL; Gao PJ
    Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):583-8. PubMed ID: 19673944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review.
    Neutel JM
    Postgrad Med; 2011 Jul; 123(4):126-34. PubMed ID: 21680997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
    Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension.
    Kochar M; Guthrie R; Triscari J; Kassler-Taub K; Reeves RA
    Am J Hypertens; 1999 Aug; 12(8 Pt 1):797-805. PubMed ID: 10480473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M; Bienfait-Beuzon C; Jackson J
    J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension.
    Neutel JM; Smith D
    J Int Med Res; 2005; 33(6):620-31. PubMed ID: 16372579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
    Mörtsell D; Malmqvist K; Held C; Kahan T
    J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.
    Pool JL; Guthrie RM; Littlejohn TW; Raskin P; Shephard AM; Weber MA; Weir MR; Wilson TW; Wright J; Kassler-Taub KB; Reeves RA
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):462-70. PubMed ID: 9607385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
    Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
    Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan.
    Jasmin JF; Calderone A; Leung TK; Villeneuve L; Dupuis J
    Cardiovasc Res; 2003 Jun; 58(3):621-31. PubMed ID: 12798435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.